Irinotecan (CPT-11) High-Dose Escalation Using Intensive High-Dose Loperamide to Control Diarrhea

洛哌丁胺 腹泻 医学 伊立替康 毒性 胃肠病学 化疗 内科学 麻醉 结直肠癌 癌症
作者
D Abigerges,P. Armand,G G Chabot,Leonardo Dourado da Costa,Élie Fadel,Claudia Côté,Patrice Herait,Daniel Gandía
出处
期刊:Journal of the National Cancer Institute [Oxford University Press]
卷期号:86 (6): 446-449 被引量:246
标识
DOI:10.1093/jnci/86.6.446
摘要

BACKGROUND: Diarrhea is a serious side effect that may prevent the administration of high doses of the antitumor drug Irinotecan (CPT-11). PURPOSE: Intensive, high-dose loperamide was used in an attempt to control or downstage CPT-11-induced diarrhea and thus permit the use of higher dose intensities of CPT-11. METHODS: Twenty-three patients with various cancers were treated with doses of CPT-11 ranging from 400 to 600 mg/m2, administered as a 30-minute intravenous infusion every 3 weeks. Starting 8 hours or more after the administration of CPT-11, any episode of diarrhea was treated with 2 mg of loperamide taken every 2 hours. Patients stopped taking loperamide only after a 12-hour diarrhea-free period. If diarrhea was not controlled after 3 consecutive days of nonstop loperamide intake, or if the patient was dehydrated, loperamide was stopped and the patient was hospitalized for intravenous fluids. If blood or mucus were found in the stools at any time during diarrhea, loperamide was stopped and the patient was hospitalized. RESULTS: Seventeen of 23 patients had diarrhea while on CPT-11 treatment. Eighty-two CPT-11 cycles were administered to these 17 patients, and diarrhea occurred in 49 of these cycles, at a median time-to-onset of 6 days after CPT-11 administration. The loperamide protocol was followed in 46 of the 49 episodes of diarrhea, with 21 capsules of loperamide the median number being taken (range, 5-72). Only one patient was hospitalized for failure to respond to loperamide, and no major toxicity was associated with loperamide use. Fourteen of the 17 patients who experienced diarrhea were rechallenged with CPT-11 three or more times, and seven patients six or more times. CONCLUSIONS: High-dose loperamide controlled diarrhea in patients receiving CPT-11 and allowed administration of higher doses of CPT-11. IMPLICATIONS: The effectiveness of CPT-11 might be increased by higher dose intensities, which can be made tolerable by control of diarrhea with loperamide.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
安安完成签到,获得积分10
1秒前
1秒前
1秒前
2秒前
奶味蓝发布了新的文献求助10
3秒前
3秒前
哇哈哈哈发布了新的文献求助10
4秒前
汉堡包的应助被尘祈风采纳,获得10
4秒前
上官若男的应助被激昂的如柏采纳,获得10
4秒前
来自北票的辉少完成签到 ,获得积分10
5秒前
lzjz发布了新的文献求助60
5秒前
bkagyin的应助被Zhixia采纳,获得10
5秒前
5秒前
七安完成签到 ,获得积分10
6秒前
6秒前
7秒前
思源的应助被安静的幼旋采纳,获得10
8秒前
西陆发布了新的文献求助10
8秒前
Harry发布了新的文献求助10
8秒前
科研陈完成签到,获得积分10
9秒前
小二郎的应助被mm采纳,获得10
9秒前
10秒前
二三完成签到,获得积分10
10秒前
11秒前
12秒前
12秒前
molihuakai的应助被zhouyang采纳,获得10
12秒前
12秒前
醋醋发布了新的文献求助10
12秒前
万事胜意完成签到,获得积分10
13秒前
玉米侠完成签到,获得积分20
13秒前
13秒前
ddk完成签到 ,获得积分10
13秒前
14秒前
14秒前
wf发布了新的文献求助10
15秒前
kuan_完成签到 ,获得积分10
15秒前
yuanvv发布了新的文献求助10
15秒前
科研通AI6.3的应助被夜泊采纳,获得10
16秒前
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8177767
求助须知:如何正确求助?哪些是违规求助? 9568590
关于积分的说明 21799821
捐赠科研通 7772374
什么是DOI,文献DOI怎么找? 3432476
关于科研通互助平台的介绍 2556695
邀请新用户注册赠送积分活动 2478034